טוען...
KIF15 nanomechanics and kinesin inhibitors, with implications for cancer chemotherapeutics
Eg5, a mitotic kinesin, has been a target for anticancer drug development. Clinical trials of small-molecule inhibitors of Eg5 have been stymied by the development of resistance, attributable to mitotic rescue by a different endogenous kinesin, KIF15. Compared with Eg5, relatively little is known ab...
שמור ב:
| הוצא לאור ב: | Proc Natl Acad Sci U S A |
|---|---|
| Main Authors: | , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
National Academy of Sciences
2018
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5960320/ https://ncbi.nlm.nih.gov/pubmed/29703754 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1073/pnas.1801242115 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|